Gabelli Funds’s Cognition Therapeutics CGTX Stock Holding History

Gabelli Funds’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.5K	Hold	30,000	–	–	﹤0.01%	1248
2026 Q1	$22.8K	Buy	+30,000	New	+$34.9K	﹤0.01%	1239

Other funds holding CGTX

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HCM

Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Gabelli Funds's CGTX Position: Q2 2026 in Review

Gabelli Funds held its Cognition Therapeutics (CGTX) position steady in Q2 2026 at 30,000 shares worth $34.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1248.

Gabelli Funds first reported a position in CGTX in Q1 2026 and has held it in 2 quarters since. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

Gabelli Funds held 30,000 shares of Cognition Therapeutics worth $34.5K as of Q2 2026.
Gabelli Funds left its Cognition Therapeutics share count unchanged in Q2 2026.
Cognition Therapeutics made up ﹤0.01% of Gabelli Funds's portfolio in Q2 2026, its #1248 holding.
Gabelli Funds first reported a position in Cognition Therapeutics in Q1 2026 and has held it in 2 quarters since.
66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Gabelli Funds's 13F filing for Q2 2026, filed 12 Aug 2026.